Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

17:10 EDT 24th May 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 25,000+

Friday 22nd May 2015

BRIEF-EU Medicines Agency gives nod for Amgen's cholesterol drug

* Recommends approval of cholesterol drug Repatha from Amgen Inc

ReNeuron CFO: Fast-track gives programme ‘best possible chance’

Michael Hunt, chief financial officer of ReNeuron (LON:RENE), says it made sense to apply for US fast track status to give its retinitis pigmentosa cell therapy candidate ‘the best possible chance’. The US Food & Drug Administration (...

IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for Solid Tumors / Company to Seek FDA Guidance to Pursue Phase 2/3 Trial of Kevetrin

BEVERLY, MA -- (Marketwired) -- 05/22/15 -- Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatolog...

bluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 10:00 a.m. ET. The conference is being held June 1-4, 2015 in New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Calendar ...

RegeneRx to Present at 2 Investor Conferences

ROCKVILLE, Md., May 22, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, chief executive officer of RegeneRx, is scheduled to present a corporate overview at two upcoming investor conferences. Mr. Finkelstein will present at the SeeThru...

Bayer wins Cancer Drugs Fund appeal

Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund reviews. The German firm’s Stivarga (regorafenib) for the treatment of gastrointestinal stromal tumours, will remain on the Fund, while Eisai’s breast cancer medicine Halaven (eribulin) and Lilly’s lung cancer drug Alimta (pemetrexed) lost their appeals and will be dropped in July. read more

WuXi adding ADC tech to services in Ambrx acquisition

A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.

US lawmakers pass new bill to speed up drug reviews

FDA will also need to take the views of patients into greater consideration under new plans

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

EMA Committee Recommends Approval of Evolocumab

Evolocumab, a first-in-class PCSK9 inhibitor that lowers LDL-cholesterol levels, is inching closer to European approval, with an EMA committee now recommending the drug be made available for selected patients. News Alerts

QT Vascular enrolls first patients in clinical study of Chocolate Touch PTCA coronary drug-coated balloon

QT Vascular, together with its subsidiaries, has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch PTCA (Coronary Drug Coated Chocolate) in the Dominican Republic.

Optibrium and Certara Collaborate on Integration of StarDrop and D360

Optibrium™ and Certara®, developers of software products and services for drug discovery and development, today announced a collaboration to provide their mutual customers with an integrated solution linking Optibrium’s StarDrop™ with Certara’s D360™ platform.  The combination of these two products enables researchers to combine the industry-leading self-ser...

FDA accepts Tris Pharma's NDA for Dyanavel XR to treat ADHD

The US Food and Drug Administration (FDA) has accepted for review Tris Pharma's new drug application (NDA) for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension, for the treatment of attention deficit hyperactivity disorder (ADHD).

Aura Biosciences gets FDA orphan disease designation for AU-011 to treat uveal melanoma

US-based biotech firm Aura Biosciences received orphan disease designation from the US Food and Drug Administration (FDA) for its drug AU-011 for the treatment of Uveal Melanoma, also referred to as Ocular Melanoma (OM).

Vortex device makes for better cancer treatments

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer.

Wockhardt gets FDA QIDP status for new pneumonia drug WCK 4873

Indian drug-maker Wockhardt has received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA) for one of its product, WCK 4873, for the treatment of pneumonia.

Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel

Entresto. That's the brand name Novartis has chosen for LCZ696, its new heart failure drug that is expected to be a blockbuster. The name won't be final until official confirmation, which comes with FDA approval. But Novartis will introduce the ...

BRIEF-GSK submits application for Japanese approval of asthma drug

* Submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

ROCKVILLE, Md., May 22, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II study evaluating RGN-259 (RegeneRx's preservative-free eye drops) for the treatment of dry eye patients using Ora Inc.'s controlled adverse environment (CAE...

Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer

WASHINGTON, May 22, 2015 /PRNewswire/ -- The Mesothelioma Victims Center is incredibly passionate about making certain diagnosed victims of mesothelioma get the best possible compensation, and they are also extremely focused on making certain individuals with this rare cancer caused by exposure to asbestos or their family have the most up-to-date information related to treatment options ...

New Emotional Core Therapy Video and Book Highlight the Most Effective and Most Inclusive Psychology Approach Available Worldwide to Treat Psychological Stress

NAPERVILLE, Ill., May 22, 2015 /PRNewswire/ -- Counselor Robert A. Moylan, LCPC has discovered, through 20 years of psychology research, the simplest and most effective behavioral psychology approach currently available in the world to treat most relationship/psychological stress, including eating disorders, addictions, depression, anxiety, anger, trauma, marital discord, sports psychology an...

Boehringer and Eureka reach cancer antibodies deal

Boehringer Ingelheim and Eureka Therapeutics have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. No financial details are being revealed at this stage but for its part of the deal, San Francisco, US-based Eureka will be applying its proprietary human sequence antibody libraries and tech towards identifying antibodies that recognise intracellular pr...

Variation in biosimilar recombinant streptokinase

A study of blood clot dissolving drug streptokinase has highlighted the mantra of ‘the process is the product’ in the case of biologicals [1].

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

SUNNYVALE, Calif., May 22, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the European Union to indicate the treatment of adult patients with...

Recycling preparative HPLC for isolation of styryl-lactones from goniothalamus lanceolatus

The forest of Borneo presents a diversity of flora and fauna which may hold the secret ingredients and compounds to treat many serious and chronic ilnesses. Researchers from ATTA-UR-Rahman Institute For Natural Product Discovery, Universiti Teknologi...

Search BioPortfolio:

News Quicklinks